Published in:
01-08-2007
Systemic inflammatory response syndrome after hand-assisted laparoscopic distal pancreatectomy
Authors:
Takeyuki Misawa, Hiroaki Shiba, Teruyuki Usuba, Takuya Nojiri, Kumiko Kitajima, Tadashi Uwagawa, Yoichi Toyama, Yuichi Ishida, Yuji Ishii, Akira Yanagisawa, Susumu Kobayashi, Katsuhiko Yanaga
Published in:
Surgical Endoscopy
|
Issue 8/2007
Login to get access
Abstract
Background
Although the clinical benefits of hand-assisted laparoscopic surgery have been shown in several procedures including colorectal resection, splenectomy and gastrectomy, efficacy and invasiveness in pancreatic surgery have not been well investigated. We assessed the clinical benefits and invasiveness of hand-assisted laparoscopic distal pancreatectomy (HALS-DP) in relation to the occurrence of post-operative systemic inflammatory response syndrome (SIRS).
Methods
Subjects comprised 8 patients underwent HALS-DP (with splenectomy, n= 7; without splenectomy, n= 1) for benign or low malignant pancreatic lesions between March 2004 and December 2005. Indications for HALS-DP consisted of mucinous cystadenoma (n= 4), endocrine tumors (n= 2), serous cystadenoma (n= 1) and pancreatic pseudocyst (n= 1). Controls comprised 9 patients who underwent conventional open distal pancreatectomy (Open-DP) for benign or low malignant lesions of the pancreas in the same period.
Results
No significant differences were identified between HALS-DP and Open-DP in operation time. However, intra-operative blood loss, CRP on post-operative day (POD) 1 [5.5 mg/dl (1.8–8.1) vs. 9.7 mg/dl (5.9–12.1); p = .006] and POD 3 [8.5 mg/dl (1.7–11.1) vs. 17.7 mg/dl (10.7–21.5); p = .003], occurrence of post-operative SIRS (13% vs. 67%; p < .05, one-sided), duration of SIRS [0 day (0–1) vs. 1 day (0–4); p = .02] and post-operative hospital stay were significantly lower in HALS-DP than in Open-DP. Furthermore, no pancreatic fistula was seen with HALS-DP, as compared to 2 (22%) with Open-DP.
Conclusion
HALS-DP is safer and less invasive than Open-DP for benign or low malignant pancreatic tumors.